Decreased levels of proapoptotic factors and increased key regulators of mitochondrial biogenesis constitute new potential beneficial features of long-lived growth hormone receptor gene-disrupted mice

Journals of Gerontology - Series A Biological Sciences and Medical Sciences

Volumn 68, Issue 6, 2013, Pages 639-651

  Gesing, Adam ^a,b   Masternak, Michal M ^c,d   Lewinski, Andrzej ^a,e   Karbownik Lewinska, Malgorzata ^a,e   Kopchick, John J ^f   Bartke, Andrzej ^b  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b SOUTHERN ILLINOIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CENTRAL FLORIDA COLLEGE OF MEDICINE   (United States)

^d INSTITUTE OF HUMAN GENETICS   (Poland)

^e POLISH MOTHER S MEMORIAL HOSPITAL RESEARCH INSTITUTE   (Poland)

^f OHIO UNIVERSITY   (United States)

Author keywords

Aging; Apoptosis; Calorie restriction; Dwarf mice; GHRKO mice; Longevity; Mitochondrial biogenesis; Visceral fat removal

Indexed keywords

MUS;

GROWTH HORMONE RECEPTOR;

AGING; ANIMAL; ANIMAL MODEL; APOPTOSIS; ARTICLE; CALORIC RESTRICTION; DWARF MICE; GENETICS; GHRKO MICE; LONGEVITY; MITOCHONDRIAL BIOGENESIS; MITOCHONDRIAL DYNAMICS; MOUSE; MOUSE MUTANT; SIGNAL TRANSDUCTION; VISCERAL FAT REMOVAL.;

AGING; APOPTOSIS; CALORIE RESTRICTION; DWARF MICE; GHRKO MICE; LONGEVITY; MITOCHONDRIAL BIOGENESIS; VISCERAL FAT REMOVAL.;

ANIMALS; APOPTOSIS; LONGEVITY; MICE; MICE, KNOCKOUT; MITOCHONDRIAL TURNOVER; MODELS, ANIMAL; RECEPTORS, SOMATOTROPIN; SIGNAL TRANSDUCTION;

EID: 84878292533     PISSN: 10795006     EISSN: 1758535X     Source Type: Journal    
DOI: 10.1093/gerona/gls231     Document Type: Article

References (169)

1. Clancy DJ, Gems D, Harshman LG, et al. Extension of life-span by loss of CHICO, a Drosophila insulin receptor substrate protein. Science. 2001;292:104-106.
2. Partridge L, Alic N, Bjedov I, Piper MD. Ageing in Drosophila: the role of the insulin/Igf and TOR signalling network. Exp Gerontol. 2011;46:376-381.
3. Kenyon CJ. The genetics of ageing. Nature. 2010;464:504-512.
4. Tissenbaum HA. Genetics, life span, health span, and the aging process in Caenorhabditis elegans. J Gerontol A Biol Sci Med Sci. 2012;67:503-510.
5. Fontana L, Partridge L, Longo VD. Extending healthy life span-from yeast to humans. Science. 2010;328:321-326.
6. Longo VD, Finch CE. Evolutionary medicine: from dwarf model systems to healthy centenarians? Science. 2003;299:1342-1346.
7. Bartke A. Single-gene mutations and healthy ageing in mammals. Philos Trans R Soc Lond, B, Biol Sci. 2011;366:28-34.
8. Zhou Y, Xu BC, Maheshwari HG, et al. A mammalian model for Laron syndrome produced by targeted disruption of the mouse growth hormone receptor/binding protein gene (the Laron mouse). Proc Natl Acad Sci USA. 1997;94:13215-13220.
9. Kopchick JJ, Laron Z. Is the Laron mouse an accurate model of Laron syndrome? Mol Genet Metab. 1999;68:232-236.
10. Coschigano KT, Clemmons D, Bellush LL, Kopchick JJ. Assessment of growth parameters and life span of GHR/BP gene-disrupted mice. Endocrinology. 2000;141:2608-2613.
11. Bartke A, Chandrashekar V, Bailey B, Zaczek D, Turyn D. Consequences of growth hormone (GH) overexpression and GH resistance. Neuropeptides. 2002;36:201-208.
12. Coschigano KT, Holland AN, Riders ME, List EO, Flyvbjerg A, Kopchick JJ. Deletion, but not antagonism, of the mouse growth hormone receptor results in severely decreased body weights, insulin, and insulin-like growth factor I levels and increased life span. Endocrinology. 2003;144:3799-3810.
13. Bartke A, Brown-Borg H. Life extension in the dwarf mouse. Curr Top Dev Biol. 2004;63:189-225.
14. Liu JL, Coschigano KT, Robertson K, et al. Disruption of growth hormone receptor gene causes diminished pancreatic islet size and increased insulin sensitivity in mice. Am J Physiol Endocrinol Metab. 2004;287:E405-E413.
15. Salmon AB, Murakami S, Bartke A, Kopchick J, Yasumura K, Miller RA. Fibroblast cell lines from young adult mice of long-lived mutant strains are resistant to multiple forms of stress. Am J Physiol Endocrinol Metab. 2005;289:E23-E29.
16. Coschigano KT. Aging-related characteristics of growth hormone receptor/binding protein gene-disrupted mice. Age (Dordr). 2006;28:191-200.
17. Harper JM, Salmon AB, Chang Y, Bonkowski M, Bartke A, Miller RA. Stress resistance and aging: influence of genes and nutrition. Mech Ageing Dev. 2006;127:687-694.
18. Sun LY, Steinbaugh MJ, Masternak MM, Bartke A, Miller RA. Fibroblasts from long-lived mutant mice show diminished ERK1/2 phosphorylation but exaggerated induction of immediate early genes. Free Radic Biol Med. 2009;47:1753-1761.
19. Ikeno Y, Hubbard GB, Lee S, et al. Reduced incidence and delayed occurrence of fatal neoplastic diseases in growth hormone receptor/binding protein knockout mice. J Gerontol A Biol Sci Med Sci. 2009;64:522-529.
20. Ding J, Berryman DE, Jara A, Kopchick JJ. Age- and sex-Associated plasma proteomic changes in growth hormone receptor gene-disrupted mice. J Gerontol A Biol Sci Med Sci. 2012;67:830-840.
21. Gesing A, Bartke A, Masternak MM, Lewiński A, Karbownik- Lewińska M. Decreased thyroid follicle size in dwarf mice may suggest the role of growth hormone signaling in thyroid growth regulation. Thyroid Res. 2012;5:7.
22. List EO, Sackmann-Sala L, Berryman DE, et al. Endocrine parameters and phenotypes of the growth hormone receptor gene disrupted (GHR-/-) mouse. Endocr Rev. 2011;32:356-386.
23. Weindruch R, Sohal RS. Seminars in medicine of the Beth Israel Deaconess Medical Center. Caloric intake and aging. N Engl J Med. 1997;337:986-994.
24. Barzilai N, She L, Liu BQ, et al. Surgical removal of visceral fat reverses hepatic insulin resistance. Diabetes. 1999;48:94-98.
25. Shi H, Strader AD, Woods SC, Seeley RJ. The effect of fat removal on glucose tolerance is depot specific in male and female mice. Am J Physiol Endocrinol Metab. 2007;293:E1012-E1020.
26. Muzumdar R, Allison DB, Huffman DM, et al. Visceral adipose tissue modulates mammalian longevity. Aging Cell. 2008;7:438-440.
27. Hock MB, Kralli A. Transcriptional control of mitochondrial biogenesis and function. Annu Rev Physiol. 2009;71:177-203.
28. Seo AY, Joseph AM, Dutta D, Hwang JC, Aris JP, Leeuwenburgh C. New insights into the role of mitochondria in aging: mitochondrial dynamics and more. J Cell Sci. 2010;123(Pt 15):2533-2542.
29. Marzetti E, Calvani R, Bernabei R, Leeuwenburgh C. Apoptosis in skeletal myocytes: a potential target for interventions against sarcopenia and physical frailty - a mini-review. Gerontology. 2012;58:99-106.
30. Clarke PG. Developmental cell death: morphological diversity and multiple mechanisms. Anat Embryol. 1990;181:195-213.
31. Favaloro B, Allocati N, Graziano V, Di Ilio C, De Laurenzi V. Role of apoptosis in disease. Aging (Albany NY). 2012;4:330-349.
32. Budihardjo I, Oliver H, Lutter M, Luo X, Wang X. Biochemical pathways of caspase activation during apoptosis. Annu Rev Cell Dev Biol. 1999;15:269-290.
33. Boatright KM, Salvesen GS. Mechanisms of caspase activation. Curr Opin Cell Biol. 2003;15:725-731.
34. Jin Z, El-Deiry WS. Overview of cell death signaling pathways. Cancer Biol Ther. 2005;4:139-163.
35. Dhahbi J, Li X, Tran T, Masternak MM, Bartke A. Circulating blood leukocyte gene expression profiles: effects of the Ames dwarf mutation on pathways related to immunity and inflammation. Exp Gerontol. 2007;42:772-788.
36. Kennedy MA, Rakoczy SG, Brown-Borg HM. Long-living Ames dwarf mouse hepatocytes readily undergo apoptosis. Exp Gerontol. 2003;38:997-1008.
37. Plant PJ, Bain JR, Correa JE, Woo M, Batt J. Absence of caspase-3 protects against denervation-induced skeletal muscle atrophy. J Appl Physiol. 2009;107:224-234.
38. Russell ST, Rajani S, Dhadda RS, Tisdale MJ. Mechanism of induction of muscle protein loss by hyperglycaemia. Exp Cell Res. 2009;315:16-25.
39. Gesing A, Masternak MM, Wang F, Lewinski A, Karbownik- Lewinska M, Bartke A. Decreased expression level of apoptosisrelated genes and/or proteins in skeletal muscles, but not in hearts, of growth hormone receptor knockout mice. Exp Biol Med (Maywood). 2011;236:156-168.
40. Faubel S, Edelstein CL. Caspases as drug targets in ischemic organ injury. Curr Drug Targets Immune Endocr Metabol Disord. 2005;5:269-287.
41. Zhang X, Zheng X, Sun H, et al. Prevention of renal ischemic injury by silencing the expression of renal caspase 3 and caspase 8. Transplantation. 2006;82:1728-1732.
42. Ali SM, Wong VY, Kikly K, et al. Apoptosis in polycystic kidney disease: involvement of caspases. Am J Physiol Regul Integr Comp Physiol. 2000;278:R763-R769.
43. Ghosh S, Khazaei M, Moien-Afshari F, et al. Moderate exercise attenuates caspase-3 activity, oxidative stress, and inhibits progression of diabetic renal disease in db/db mice. Am J Physiol Renal Physiol. 2009;296:F700-F708.
44. Chen YW, Chenier I, Chang SY, Tran S, Ingelfinger JR, Zhang SL. High glucose promotes nascent nephron apoptosis via NF-kappaB and p53 pathways. Am J Physiol Renal Physiol. 2011;300:F147-F156.
45. Tao Y, Zafar I, Kim J, Schrier RW, Edelstein CL. Caspase-3 gene deletion prolongs survival in polycystic kidney disease. J Am Soc Nephrol. 2008;19:749-755.
46. Gesing A, Bartke A, Wang F, Karbownik-Lewinska M, Masternak MM. Renal pro-Apoptotic proteins are reduced by growth hormone resistance but not by visceral fat removal. Biol Chem. 2011;392:475-481.
47. Gesing A, Masternak MM, Wang F, Karbownik-Lewinska M, Bartke A. Deletion of growth hormone receptor gene but not visceral fat removal decreases expression of apoptosis-related genes in the kidney-potential mechanism of lifespan extension. Age (Dordr). 2012;34:295-304.
48. Mishra R, Emancipator SN, Kern T, Simonson MS. High glucose evokes an intrinsic proapoptotic signaling pathway in mesangial cells. Kidney Int. 2005;67:82-93.
49. Kruidering M, Evan GI. Caspase-8 in apoptosis: the beginning of "the end"? IUBMB Life. 2000;50:85-90.
50. Wencker D, Chandra M, Nguyen K, et al. A mechanistic role for cardiac myocyte apoptosis in heart failure. J Clin Invest. 2003;111: 1497-1504.
51. Coultas L, Strasser A. The role of the Bcl-2 protein family in cancer. Semin Cancer Biol. 2003;13:115-123.
52. Li Q, Ren J. Influence of cardiac-specific overexpression of insulinlike growth factor 1 on lifespan and aging-Associated changes in cardiac intracellular Ca2+ homeostasis, protein damage and apoptotic protein expression. Aging Cell. 2007;6:799-806.
53. Hochhauser E, Kivity S, Offen D, et al. Bax ablation protects against myocardial ischemia-reperfusion injury in transgenic mice. Am J Physiol Heart Circ Physiol. 2003;284:H2351-H2359.
54. Wang Z, Havasi A, Gall JM, Mao H, Schwartz JH, Borkan SC. Betacatenin promotes survival of renal epithelial cells by inhibiting Bax. J Am Soc Nephrol. 2009;20:1919-1928.
55. Zhou D, Li Y, Lin L, Zhou L, Igarashi P, Liu Y. Tubule-specific ablation of endogenous β-catenin aggravates acute kidney injury in mice. Kidney Int. 2012;82:537-547.
56. Ortiz A, Ziyadeh FN, Neilson EG. Expression of apoptosis-regulatory genes in renal proximal tubular epithelial cells exposed to high ambient glucose and in diabetic kidneys. J Investig Med. 1997;45:50-56.
57. Srinivasula SM, Datta P, Fan XJ, Fernandes-Alnemri T, Huang Z, Alnemri ES. Molecular determinants of the caspase-promoting activity of Smac/DIABLO and its role in the death receptor pathway. J Biol Chem. 2000;275:36152-36157.
58. Henry-Mowatt J, Dive C, Martinou JC, James D. Role of mitochondrial membrane permeabilization in apoptosis and cancer. Oncogene. 2004;23:2850-2860.
59. Zha J, Harada H, Yang E, Jockel J, Korsmeyer SJ. Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not BCL-X(L). Cell. 1996;87:619-628.
60. Zou H, Li Y, Liu X, Wang X. An APAF-1 cytochrome c multimeric complex is a functional apoptosome that activates procaspase-9. J Biol Chem. 1999;274:11549-11556.
61. Adrain C, Martin SJ. The mitochondrial apoptosome: a killer unleashed by the cytochrome seas. Trends Biochem Sci. 2001;26:390-397.
62. Park HH. Structural features of caspase-Activating complexes. Int J Mol Sci. 2012;13:4807-4818.
63. Reubold TF, Eschenburg S. A molecular view on signal transduction by the apoptosome. Cell Signal. 2012;24:1420-1425.
64. Miyazawa M, Ishii T, Yasuda K, et al. The role of mitochondrial superoxide anion (O2(-)) on physiological aging in C57BL/6J mice. J Radiat Res. 2009;50:73-83.
65. Gross A, McDonnell JM, Korsmeyer SJ. BCL-2 family members and the mitochondria in apoptosis. Genes Dev. 1999;13:1899-1911.
66. Tyner SD, Venkatachalam S, Choi J, et al. p53 mutant mice that display early ageing-Associated phenotypes. Nature. 2002;415:45-53.
67. Campisi J. Senescent cells, tumor suppression, and organismal aging: good citizens, bad neighbors. Cell. 2005;120:513-522.
68. Shizukuda Y, Matoba S, Mian OY, Nguyen T, Hwang PM. Targeted disruption of p53 attenuates doxorubicin-induced cardiac toxicity in mice. Mol Cell Biochem. 2005;273:25-32.
69. Matsusaka H, Ide T, Matsushima S, et al. Targeted deletion of p53 prevents cardiac rupture after myocardial infarction in mice. Cardiovasc Res. 2006;70:457-465.
70. Nakamura H, Matoba S, Iwai-Kanai E, et al. p53 promotes cardiac dysfunction in diabetic mellitus caused by excessive mitochondrial respiration-mediated reactive oxygen species generation and lipid accumulation. Circ Heart Fail. 2012;5:106-115.
71. Wei Q, Dong G, Yang T, Megyesi J, Price PM, Dong Z. Activation and involvement of p53 in cisplatin-induced nephrotoxicity. Am J Physiol Renal Physiol. 2007;293:F1282-F1291.
72. Kim DH, Jung YJ, Lee JE, et al. SIRT1 activation by resveratrol ameliorates cisplatin-induced renal injury through deacetylation of p53. Am J Physiol Renal Physiol. 2011;301:F427-F435.
73. Zhou L, Fu P, Huang XR, Liu F, Lai KN, Lan HY. Activation of p53 promotes renal injury in acute aristolochic acid nephropathy. J Am Soc Nephrol. 2010;21:31-41.
74. Shieh SY, Ikeda M, Taya Y, Prives C. DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2. Cell. 1997;91:325-334.
75. Ashkenazi A. Directing cancer cells to self-destruct with pro-Apoptotic receptor agonists. Nat Rev Drug Discov. 2008;7:1001-1012.
76. Sorenson CM, Padanilam BJ, Hammerman MR. Abnormal postpartum renal development and cystogenesis in the bcl-2 (-/-) mouse. Am J Physiol. 1996;271(1 Pt 2):F184-F193.
77. Sorenson CM. Bcl-2 family members and disease. Biochim Biophys Acta. 2004;1644:169-177.
78. Joseph AM, Joanisse DR, Baillot RG, Hood DA. Mitochondrial dysregulation in the pathogenesis of diabetes: potential for mitochondrial biogenesis-mediated interventions. Exp Diabetes Res. 2012;2012:642038. doi: 10.1155/2012/642038
79. Dillon LM, Rebelo AP, Moraes CT. The role of PGC-1 coactivators in aging skeletal muscle and heart. IUBMB Life. 2012;64:231-241.
80. Puigserver P, Wu Z, Park CW, Graves R, Wright M, Spiegelman BM. A cold-inducible coactivator of nuclear receptors linked to adaptive thermogenesis. Cell. 1998;92:829-839.
81. Liang H, Ward WF. PGC-1 alpha: a key regulator of energy metabolism. Adv Physiol Educ. 2006;30:145-151.
82. Lin J, Wu PH, Tarr PT, et al. Defects in adaptive energy metabolism with CNS-linked hyperactivity in PGC-1alpha null mice. Cell. 2004;119:121-135.
83. Boström P, Wu J, Jedrychowski MP, et al. A PGC1-α-dependent myokine that drives brown-fat-like development of white fat and thermogenesis. Nature. 2012;481:463-468.
84. Gesing A, Masternak MM, Wang F, et al. Expression of key regulators of mitochondrial biogenesis in growth hormone receptor knockout (GHRKO) mice is enhanced but is not further improved by other potential life-extending interventions. J Gerontol A Biol Sci Med Sci. 2011;66:1062-1076.
85. Gesing A, Bartke A, Wang F, Karbownik-Lewinska M, Masternak MM. Key regulators of mitochondrial biogenesis are increased in kidneys of growth hormone receptor knockout (GHRKO) mice. Cell Biochem Funct. 2011;29:459-467.
86. Moslehi J, DePinho RA, Sahin E. Telomeres and mitochondria in the aging heart. Circ Res. 2012;110:1226-1237.
87. Reznick RM, Zong H, Li J, et al. Aging-Associated reductions in AMP-Activated protein kinase activity and mitochondrial biogenesis. Cell Metab. 2007;5:151-156.
88. Jäger S, Handschin C, St-Pierre J, Spiegelman BM. AMPactivated protein kinase (AMPK) action in skeletal muscle via direct phosphorylation of PGC-1alpha. Proc Natl Acad Sci USA. 2007;104:12017-12022.
89. Ceddia RB. The role of AMP-Activated protein kinase in regulating white adipose tissue metabolism. Mol Cell Endocrinol. 2012;32: 607-616. doi: 10.1016/j.mce.2012.06.014
90. Dolinsky VW, Dyck Jr. Role of AMP-Activated protein kinase in healthy and diseased hearts. Am J Physiol Heart Circ Physiol. 2006;291:H2557-H2569.
91. Dyck JR, Lopaschuk GD. AMPK alterations in cardiac physiology and pathology: enemy or ally? J Physiol (Lond). 2006;574(Pt 1):95-112.
92. Stuck BJ, Lenski M, Böhm M, Laufs U. Metabolic switch and hypertrophy of cardiomyocytes following treatment with angiotensin II are prevented by AMP-Activated protein kinase. J Biol Chem. 2008;283:32562-32569.
93. Xie Z, He C, Zou MH. AMP-Activated protein kinase modulates cardiac autophagy in diabetic cardiomyopathy. Autophagy. 2011;7:1254-1255.
94. Russell RR 3rd, Li J, Coven DL, et al. AMP-Activated protein kinase mediates ischemic glucose uptake and prevents postischemic cardiac dysfunction, apoptosis, and injury. J Clin Invest. 2004;114:495-503.
95. Turdi S, Kandadi MR, Zhao J, Huff AF, Du M, Ren J. Deficiency in AMPactivated protein kinase exaggerates high fat diet-induced cardiac hypertrophy and contractile dysfunction. J Mol Cell Cardiol. 2011;50:712-722.
96. Lieberthal W, Zhang L, Patel VA, Levine JS. AMPK protects proximal tubular cells from stress-induced apoptosis by an ATPindependent mechanism: potential role of Akt activation. Am J Physiol Renal Physiol. 2011;301:F1177-F1192.
97. Takiar V, Nishio S, Seo-Mayer P, et al. Activating AMP-Activated protein kinase (AMPK) slows renal cystogenesis. Proc Natl Acad Sci USA. 2011;108:2462-2467.
98. Baur JA, Ungvari Z, Minor RK, Le Couteur DG, de Cabo R. Are sirtuins viable targets for improving healthspan and lifespan? Nat Rev Drug Discov. 2012;11:443-461.
99. Rodgers JT, Lerin C, Gerhart-Hines Z, Puigserver P. Metabolic adaptations through the PGC-1 alpha and SIRT1 pathways. FEBS Lett. 2008;582:46-53.
100. Sequeira J, Boily G, Bazinet S, et al. sirt1-null mice develop an autoimmune- like condition. Exp Cell Res. 2008;314:3069-3074.
101. Kong S, McBurney MW, Fang D. Sirtuin 1 in immune regulation and autoimmunity. Immunol Cell Biol. 2012;90:6-13.
102. Hsu CP, Odewale I, Alcendor RR, Sadoshima J. Sirt1 protects the heart from aging and stress. Biol Chem. 2008;389:221-231.
103. Hsu CP, Zhai P, Yamamoto T, et al. Silent information regulator 1 protects the heart from ischemia/reperfusion. Circulation. 2010;122:2170-2182.
104. Vinciguerra M, Santini MP, Martinez C, et al. mIGF-1/JNK1/SirT1 signaling confers protection against oxidative stress in the heart. Aging Cell. 2012;11:139-149.
105. Wang RH, Sengupta K, Li C, et al. Impaired DNA damage response, genome instability, and tumorigenesis in SIRT1 mutant mice. Cancer Cell. 2008;14:312-323.
106. Kawashima T, Inuzuka Y, Okuda J, et al. Constitutive SIRT1 overexpression impairs mitochondria and reduces cardiac function in mice. J Mol Cell Cardiol. 2011;51:1026-1036.
107. Shi T, Wang F, Stieren E, Tong Q. SIRT3, a mitochondrial sirtuin deacetylase, regulates mitochondrial function and thermogenesis in brown adipocytes. J Biol Chem. 2005;280:13560-13567.
108. Allison SJ, Milner J. SIRT3 is pro-Apoptotic and participates in distinct basal apoptotic pathways. Cell Cycle. 2007;6:2669-2677.
109. Green MF, Hirschey MD. SIRT3 Weighs Heavily in the Metabolic Balance: A New Role for SIRT3 in Metabolic Syndrome. J Gerontol A Biol Sci Med Sci. 2012. doi:10.1093/gerona/gls132
110. Sundaresan NR, Gupta M, Kim G, Rajamohan SB, Isbatan A, Gupta MP. Sirt3 blocks the cardiac hypertrophic response by augmenting Foxo3a-dependent antioxidant defense mechanisms in mice. J Clin Invest. 2009;119:2758-2771.
111. Liu Y, Zhang D, Chen D. SIRT3: Striking at the heart of aging. Aging (Albany NY). 2011;3:1-2.
112. Palacios OM, Carmona JJ, Michan S, et al. Diet and exercise signals regulate SIRT3 and activate AMPK and PGC-1alpha in skeletal muscle. Aging (Albany NY). 2009;1:771-783.
113. Mostoslavsky R, Chua KF, Lombard DB, et al. Genomic instability and aging-like phenotype in the absence of mammalian SIRT6. Cell. 2006;124:315-329.
114. Michishita E, McCord RA, Berber E, et al. SIRT6 is a histone H3 lysine 9 deacetylase that modulates telomeric chromatin. Nature. 2008;452:492-496.
115. Mao Z, Hine C, Tian X, et al. SIRT6 promotes DNA repair under stress by activating PARP1. Science. 2011;332:1443-1446.
116. Van Meter M, Mao Z, Gorbunova V, Seluanov A. SIRT6 overexpression induces massive apoptosis in cancer cells but not in normal cells. Cell Cycle. 2011;10:3153-3158.
117. Kanfi Y, Peshti V, Gil R, et al. SIRT6 protects against pathological damage caused by diet-induced obesity. Aging Cell. 2010;9:162-173.
118. Kanfi Y, Naiman S, Amir G, et al. The sirtuin SIRT6 regulates lifespan in male mice. Nature. 2012;483:218-221.
119. Naiman S, Kanfi Y, Cohen HY. Sirtuins as regulators of mammalian aging. Aging (Albany NY). 2012;4:521-522.
120. Leary SC, Shoubridge EA. Mitochondrial biogenesis: which part of "NO" do we understand? Bioessays. 2003;25:538-541.
121. Nisoli E, Clementi E, Paolucci C, et al. Mitochondrial biogenesis in mammals: the role of endogenous nitric oxide. Science. 2003;299:896-899.
122. Yu J, deMuinck ED, Zhuang Z, et al. Endothelial nitric oxide synthase is critical for ischemic remodeling, mural cell recruitment, and blood flow reserve. Proc Natl Acad Sci USA. 2005;102:10999-11004.
123. Mungrue IN, Bredt DS, Stewart DJ, Husain M. From molecules to mammals: what's NOS got to do with it? Acta Physiol Scand. 2003;179:123-135.
124. Duplain H, Burcelin R, Sartori C, et al. Insulin resistance, hyperlipidemia, and hypertension in mice lacking endothelial nitric oxide synthase. Circulation. 2001;104:342-345.
125. Nakayama T, Sato W, Kosugi T, et al. Endothelial injury due to eNOS deficiency accelerates the progression of chronic renal disease in the mouse. Am J Physiol Renal Physiol. 2009;296:F317-F327.
126. Milsom AB, Patel NS, Mazzon E, et al. Role for endothelial nitric oxide synthase in nitrite-induced protection against renal ischemiareperfusion injury in mice. Nitric Oxide. 2010;22:141-148.
127. Pointer MA, Daumerie G, Bridges L, et al. Physiological stress increases renal injury in eNOS-knockout mice. Hypertens Res. 2012;35:318-324.
128. Gava AL, Peotta VA, Cabral AM, Vasquez EC, Meyrelles SS. Overexpression of eNOS prevents the development of renovascular hypertension in mice. Can J Physiol Pharmacol. 2008;86:458-464.
129. Cheng H, Wang H, Fan X, Paueksakon P, Harris RC. Improvement of endothelial nitric oxide synthase activity retards the progression of diabetic nephropathy in db/db mice. Kidney Int. 2012. doi:10.1038/ki.2012.248
130. Durand JL, Nawrocki AR, Scherer PE, Jelicks LA. Gender differences in adiponectin modulation of cardiac remodeling in mice deficient in endothelial nitric oxide synthase. J Cell Biochem. 2012;113:3276-3287.
131. Wu Z, Puigserver P, Andersson U, et al. Mechanisms controlling mitochondrial biogenesis and respiration through the thermogenic coactivator PGC-1. Cell. 1999;98:115-124.
132. Scarpulla RC. Transcriptional paradigms in mammalian mitochondrial biogenesis and function. Physiol Rev. 2008;88:611-638.
133. Larsson NG, Wang J, Wilhelmsson H, et al. Mitochondrial transcription factor A is necessary for mtDNA maintenance and embryogenesis in mice. Nat Genet. 1998;18:231-236.
134. Wang J, Wilhelmsson H, Graff C, et al. Dilated cardiomyopathy and atrioventricular conduction blocks induced by heart-specific inactivation of mitochondrial DNA gene expression. Nat Genet. 1999;21:133-137.
135. Holmström MH, Iglesias-Gutierrez E, Zierath JR, Garcia-Roves PM. Tissue-specific control of mitochondrial respiration in obesityrelated insulin resistance and diabetes. Am J Physiol Endocrinol Metab. 2012;302:E731-E739.
136. Ikeuchi M, Matsusaka H, Kang D, et al. Overexpression of mitochondrial transcription factor a ameliorates mitochondrial deficiencies and cardiac failure after myocardial infarction. Circulation. 2005;112:683-690.
137. Kang D, Kim SH, Hamasaki N. Mitochondrial transcription factor A (TFAM): roles in maintenance of mtDNA and cellular functions. Mitochondrion. 2007;7:39-44.
138. Pesce V, Cormio A, Fracasso F, Lezza AM, Cantatore P, Gadaleta MN. Age-related changes of mitochondrial DNA content and mitochondrial genotypic and phenotypic alterations in rat hind-limb skeletal muscles. J Gerontol A Biol Sci Med Sci. 2005;60:715-723.
139. Bach D, Pich S, Soriano FX, et al. Mitofusin-2 determines mitochondrial network architecture and mitochondrial metabolism. A novel regulatory mechanism altered in obesity. J Biol Chem. 2003;278:17190-17197.
140. Koshiba T, Detmer SA, Kaiser JT, Chen H, McCaffery JM, Chan DC. Structural basis of mitochondrial tethering by mitofusin complexes. Science. 2004;305:858-862.
141. Bach D, Naon D, Pich S, et al. Expression of Mfn2, the Charcot- Marie-Tooth neuropathy type 2A gene, in human skeletal muscle: effects of type 2 diabetes, obesity, weight loss, and the regulatory role of tumor necrosis factor alpha and interleukin-6. Diabetes. 2005;54:2685-2693.
142. Soriano FX, Liesa M, Bach D, Chan DC, Palacín M, Zorzano A. Evidence for a mitochondrial regulatory pathway defined by peroxisome proliferator-Activated receptor-gamma coactivator-1 alpha, estrogen-related receptor-Alpha, and mitofusin 2. Diabetes. 2006;55:1783-1791.
143. Adhihetty PJ, Uguccioni G, Leick L, Hidalgo J, Pilegaard H, Hood DA. The role of PGC-1alpha on mitochondrial function and apoptotic susceptibility in muscle. Am J Physiol, Cell Physiol. 2009;297:C217-C225.
144. Fang L, Moore XL, Gao XM, Dart AM, Lim YL, Du XJ. Downregulation of mitofusin-2 expression in cardiac hypertrophy in vitro and in vivo. Life Sci. 2007;80:2154-2160.
145. Gall JM, Wang Z, Liesa M, et al. Role of mitofusin 2 in the renal stress response. PLoS ONE. 2012;7:e31074.
146. Heydari AR, Unnikrishnan A, Lucente LV, Richardson A. Caloric restriction and genomic stability. Nucleic Acids Res. 2007;35:7485-7496.
147. Mercken EM, Carboneau BA, Krzysik-Walker SM, de Cabo R. Of mice and men: the benefits of caloric restriction, exercise, and mimetics. Ageing Res Rev. 2012;11:390-398.
148. Nisoli E, Tonello C, Cardile A, et al. Calorie restriction promotes mitochondrial biogenesis by inducing the expression of eNOS. Science. 2005;310:314-317.
149. López-Lluch G, Hunt N, Jones B, et al. Calorie restriction induces mitochondrial biogenesis and bioenergetic efficiency. Proc Natl Acad Sci USA. 2006;103:1768-1773.
150. López-Lluch G, Irusta PM, Navas P, de Cabo R. Mitochondrial biogenesis and healthy aging. Exp Gerontol. 2008;43:813-819.
151. Civitarese AE, Carling S, Heilbronn LK, et al. Calorie restriction increases muscle mitochondrial biogenesis in healthy humans. PLoS Med. 2007;4:e76.
152. Bonkowski MS, Rocha JS, Masternak MM, Al Regaiey KA, Bartke A. Targeted disruption of growth hormone receptor interferes with the beneficial actions of calorie restriction. Proc Natl Acad Sci USA. 2006;103:7901-7905.
153. Bonkowski MS, Dominici FP, Arum O, et al. Disruption of growth hormone receptor prevents calorie restriction from improving insulin action and longevity. PLoS ONE. 2009;4:e4567.
154. Giani JF, Bonkowski MS, Muñoz MC, et al. Insulin signaling cascade in the hearts of long-lived growth hormone receptor knockout mice: effects of calorie restriction. J Gerontol A Biol Sci Med Sci. 2008;63:788-797.
155. Chen Y, Hagopian K, McDonald RB, et al. The influence of dietary lipid composition on skeletal muscle mitochondria from mice following 1 month of calorie restriction. J Gerontol A Biol Sci Med Sci. 2012;67:1121-1131.
156. Miller BF, Robinson MM, Bruss MD, Hellerstein M, Hamilton KL. A comprehensive assessment of mitochondrial protein synthesis and cellular proliferation with age and caloric restriction. Aging Cell. 2012;11:150-161.
157. Hancock CR, Han DH, Higashida K, Kim SH, Holloszy JO. Does calorie restriction induce mitochondrial biogenesis? A reevaluation. FASEB J. 2011;25:785-791.
158. Finley LW, Lee J, Souza A, et al. Skeletal muscle transcriptional coactivator PGC-1α mediates mitochondrial, but not metabolic, changes during calorie restriction. Proc Natl Acad Sci USA. 2012;109:2931-2936.
159. Zhang HH, Kumar S, Barnett AH, Eggo MC. Dexamethasone inhibits tumor necrosis factor-Alpha-induced apoptosis and interleukin-1 beta release in human subcutaneous adipocytes and preadipocytes. J Clin Endocrinol Metab. 2001;86:2817-2825.
160. Fasshauer M, Paschke R. Regulation of adipocytokines and insulin resistance. Diabetologia. 2003;46:1594-1603.
161. Lagathu C, Bastard JP, Auclair M, Maachi M, Capeau J, Caron M. Chronic interleukin-6 (IL-6) treatment increased IL-6 secretion and induced insulin resistance in adipocyte: prevention by rosiglitazone. Biochem Biophys Res Commun. 2003;311:372-379.
162. Berryman DE, List EO, Coschigano KT, Behar K, Kim JK, Kopchick JJ. Comparing adiposity profiles in three mouse models with altered GH signaling. Growth Horm IGF Res. 2004;14:309-318.
163. Masternak MM, Bartke A, Wang F, et al. Metabolic effects of intraabdominal fat in GHRKO mice. Aging Cell. 2012;11:73-81.
164. Huffman DM, Barzilai N. Role of visceral adipose tissue in aging. Biochim Biophys Acta. 2009;1790:1117-1123.
165. Foster MT, Shi H, Seeley RJ, Woods SC. Removal of intra-Abdominal visceral adipose tissue improves glucose tolerance in rats: role of hepatic triglyceride storage. Physiol Behav. 2011;104:845-854.
166. Fabbrini E, Tamboli RA, Magkos F, et al. Surgical removal of omental fat does not improve insulin sensitivity and cardiovascular risk factors in obese adults. Gastroenterology. 2010;139:448-455.
167. Minor RK, Allard JS, Younts CM, Ward TM, de Cabo R. Dietary interventions to extend life span and health span based on calorie restriction. J Gerontol A Biol Sci Med Sci. 2010;65:695-703.
168. Le Couteur DG, McLachlan AJ, de Cabo R. Aging, drugs, and drug metabolism. J Gerontol A Biol Sci Med Sci. 2012;67: 137-139.
169. Le Couteur DG, McLachlan AJ, Quinn RJ, Simpson SJ, de Cabo R. Aging biology and novel targets for drug discovery. J Gerontol A Biol Sci Med Sci. 2012;67:168-174.